Clinical Trials Browser

Phase 2 × Completed × tislelizumab × Clear all

NCT05116085 2026-02-13

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Phase 2 Completed

33 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05622071 2025-11-17

HESTIA

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04047186 2025-09-23

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Phase 2 Completed

Lung Neoplasms, Multiple Pulmonary Nodules

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

Phase 2 Completed

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05880082 2025-08-24

PPIO-004-EC001

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Phase 2 Completed

Gastrointestinal

Mid-low Rectal Cancer

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

Ovarian Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05542342 2025-05-14

SITISVEAL

Phase 2 Completed

Uveal Melanoma

NCT04693234 2025-04-27

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

178 enrolled 26 charts

Uterine Cervical Neoplasms

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase 2 Completed

84 enrolled 17 charts

Other solid neoplasm

Advanced Solid Tumors

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Immunotherapy

NCT05058560 2025-03-13

Tislelizumab in Addition to BACE in Patients with NSCLC

Phase 2 Completed

NSCLC

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04732494 2025-01-31

AdvanTIG-203

Phase 2 Completed

125 enrolled 25 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03419897 2024-10-26

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Phase 2 Completed

249 enrolled 24 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 Completed

77 enrolled 20 charts

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT04004221 2024-10-26

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2 Completed

113 enrolled 15 charts

Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04952597 2024-10-26

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Phase 2 Completed

126 enrolled 19 charts

Limited Stage Small Cell Lung Cancer

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Phase 2 Completed

Lung Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Phase 2 Completed

Gastrointestinal

Locally Advanced Rectal Cancer

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT06238752 2024-02-02

RENMIN-213

Phase 2 Completed

Adenocarcinoma

NCT04507217 2023-05-25

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Phase 2 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung